<DOC>
	<DOCNO>NCT01763931</DOCNO>
	<brief_summary>The purpose study learn effect digoxin may human breast cancer tissue .</brief_summary>
	<brief_title>DIG-HIF1 Pharmacodynamic Trial Newly Diagnosed Operable Breast Cancer</brief_title>
	<detailed_description>Breast cancer cell grow low oxygen environment call hypoxia . Your body normally control amount oxygen cell know HIF-1 , hypoxia inducible factor 1 . HIF-1 help cancer cell grow low oxygen environment ; therefore , able block function , may make hard breast cancer cell grow . Digoxin drug show block HIF-1 lab study . We want learn block HIF-1 human breast cancer tissue . We compare tumor tissue original diagnostic biopsy tissue take time surgery . We also compare tumor tissue patient randomize take digoxin .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>Female sex 1870 year age time consent . Histologically confirm infiltrate carcinoma breast ( Stage IIII ) Unresected disease meet schedule undergo definitive surgery ; tumor size ≥ 1cm ; grade 2 3 tumor Ki67 proliferation index ≥ 10 % ; , ER , PR HER2 status Patients must receive prior treatment kind treat current breast cancer . Prior use hormone contraceptive replacement therapy allow , must discontinue least 30 day prior diagnostic biopsy . ECOG performance status 0 1 ( Karnofsky 80 % 100 % ) Patients must normal organ marrow function : absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ; platelet count ≥ 100,000/mm3 ; bilirubin ( total ) less equal upper limit normal ; creatinine ≤ 1.5 time upper limit normal creatinine clearance ≥ 50 mL/min use Modified CockcroftGault method ; , follow within normal limit : thyroid stimulate hormone ( TSH ) , magnesium , potassium , sodium , calcium . Heart rate &gt; 60 beats/minute &lt; 100 beats/minute ( clinical exam ) . Not pregnant nursing Ability understand willingness sign write informed consent document Current use investigational agent Radiological evidence metastatic disease History allergic reaction attribute compound similar chemical biologic composition digoxin Concomitant use drug baseline duration digoxin administration ( randomized receive ) : calcium channel blocker diltiazem verapamil ; cardiac arrhythmic agent ( quinidine , amiodarone ) ; indomethacin ( Indocin ) ; alprazolam ( Xanax ) ; diuretic ( furosemide , spironolactone , itraconazole ) ; betablockers ( atenolol , metoprolol ) ; calcium carbonate antacid ( e.g. , Maalox , Tums , Rolaids ) ; proton pump inhibitor ; antidiarrheal adsorbent ( kaolin pectin ) ; antibiotic ; P450 inducer/inhibitors . NOTE : Patients already receive digoxin also exclude . Presence follow electrocardiogram ( ECG ) : atrial arrhythmia , include atrial fibrillation flutter ; AV block ; heart rate &lt; 60 beats/minute &gt; 100 beats/minute ; ventricular Fibrillation ; ventricular tachycardia ; premature ventricular contraction ; WolffParkinsonWhite syndrome . NOTE : Any question cardiac eligibility review Study Cardiologist approval advance enrollment . History follow , unless approval give Protocol Chair : heart disease , include acute myocardial infarction ; cardiac arrhythmia , include sick sinus syndrome ; pulmonary disease know FEV &lt; 1.5 oxygen ; gastrointestinal disease , surgery malabsorption could potentially impact absorption study drug ; patient require use feed tube ; inability swallow tablet Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation limit compliance study requirement Any medical condition opinion investigator put patient risk potentially serious complication therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Digoxin</keyword>
</DOC>